During the recent session, Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s traded shares were 5.11 million, with the beta value of the company hitting 1.46. At the last check today, the stock’s price was $10.98, reflecting an intraday gain of 2.28% or $0.25. The 52-week high for the TEVA share is $13.30, that puts it down -21.13 from that peak though still a striking 23.13% gain since the share price plummeted to a 52-week low of $8.44. The company’s market capitalization is $12.21B, and the average intraday trading volume over the past 10 days was 7.06 million shares, and the average trade volume was 7.91 million shares over the past three months.
Teva Pharmaceutical Industries Limited (TEVA) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.90. TEVA has a Sell rating from 1 analyst(s) out of 22 analysts who have looked at this stock. 16 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 3 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.59.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) trade information
Teva Pharmaceutical Industries Limited (TEVA) registered a 2.28% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.28% in intraday trading to $10.98 this Wednesday, 06/09/21, hitting a weekly high. The stock’s 5-day price performance is 1.13%, and it has moved by 4.68% in 30 days. Based on these gigs, the overall price performance for the year is -15.04%. The short interest in Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 35.16 million shares and it means that shorts have 4.55 day(s) to cover.
The consensus price target of analysts on Wall Street is $11.81, which implies an increase of 7.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $17.00 respectively. As a result, TEVA is trading at a discount of -54.83% off the target high and 18.03% off the low.
Teva Pharmaceutical Industries Limited (TEVA) estimates and forecasts
Statistics show that Teva Pharmaceutical Industries Limited has underperformed its competitors in share price, compared to the industry in which it operates. Teva Pharmaceutical Industries Limited (TEVA) shares have gone up 6.66% during the last six months, with a year-to-date growth rate less than the industry average at 2.72% against 5.00. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 7.30% this quarter and then jump 13.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -0.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $4.02 billion as predicted by 16 analyst(s). Meanwhile, a consensus of 16 analyst(s) estimates revenue growth to $4.11 billion by the end of Sep 2021.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -32.00%. While earnings are projected to return -297.90% in 2021, the next five years will return 5.77% per annum.
Teva Pharmaceutical Industries Limited is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s Major holders
Teva Pharmaceutical Industries Limited insiders own 1.06% of total outstanding shares while institutional holders control 52.54%, with the float percentage being 53.10%. Capital Research Global Investors is the largest shareholder of the company, while 643 institutions own stock in it. As of Mar 30, 2021, the company held over 128.69 million shares (or 11.78% of all shares), a total value of $1.49 billion in shares.
The next largest institutional holding, with 53.02 million shares, is of Capital World Investors’s that is approximately 4.85% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $611.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of Teva Pharmaceutical Industries Limited (TEVA) shares are Europacific Growth Fund and Growth Fund Of America Inc. Data provided on Dec 30, 2020 indicates that Europacific Growth Fund owns about 56.13 million shares. This amounts to just over 5.14 percent of the company’s overall shares, with a $541.7 million market value. The same data shows that the other fund manager holds slightly less at 49.37 million, or about 4.52% of the stock, which is worth about $569.74 million.